Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marlanka A Zuur

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2018
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis ProgramsMarlanka A Zuur, Jotam G Pasipanodya, Dick van Soolingen, et al.
The European Respiratory Journal|September 3, 2016
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?Marlanka A Zuur, Onno W Akkerman, Lina Davies Forsman, et al.
The European Respiratory Journal|June 12, 2016
Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIVMarlanka A Zuur, Onno W Akkerman, Daan J Touw, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 8, 2016
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosisMarlanka A Zuur, Mathieu S Bolhuis, Richard Anthony, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i>Sander P van Rijn, Marlanka A Zuur, Richard Anthony, et al.
Therapeutic Drug Monitoring|June 7, 2019
Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 CountriesMarlanka A Zuur, Herman Veenhof, Alena Aleksa, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2018
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis ProgramsMarlanka A Zuur, Jotam G Pasipanodya, Dick van Soolingen, et al.
The European Respiratory Journal|September 3, 2016
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?Marlanka A Zuur, Onno W Akkerman, Lina Davies Forsman, et al.
The European Respiratory Journal|June 12, 2016
Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIVMarlanka A Zuur, Onno W Akkerman, Daan J Touw, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 8, 2016
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosisMarlanka A Zuur, Mathieu S Bolhuis, Richard Anthony, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i>Sander P van Rijn, Marlanka A Zuur, Richard Anthony, et al.
Therapeutic Drug Monitoring|June 7, 2019
Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 CountriesMarlanka A Zuur, Herman Veenhof, Alena Aleksa, et al.
Pageof 1